Management of Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Saturday, April 1, 2017
7:00 – 9:30 pm
Hyatt Regency Orlando- Regency Ballroom S 
This activity is supported by an educational grant from Eisai Inc.

CLICK "BEGIN" TO EVALUATE SESSIONS, CLAIM CME, AND PRINT A CERTIFICATE OF ATTENDANCE OR CERTIFICATE OF PARTICIPATION.

Target Audience

This continuing medical education activity should be of substantial interest to the community of clinical endocrinologists, internists, primary care physicians, endocrine nurses, and other healthcare providers involved in the care of patients with thyroid cancer.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Personalize treatment selection for patients with RAI-refractory DTC based on available data and approved agents
  • Mitigate and manage adverse events to preserve patient function and improve outcomes
  • Review late-stage clinical trials of emerging agents for which patients with RAI-refractory DTC may be eligible

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Lipid Disorders and Fatty Liver Diseases
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Level 6 (Patient Health)
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
03/30/2017
Course expires: 
04/01/2018
Rating: 
5
Program Director
Steven I. Sherman, MD
Associate Vice Provost, Clinical Research
Naguib Samaan Distinguished Professor in Endocrinology
Chair, Department of Endocrine Neoplasia and Hormonal Disorders
The University of Texas MD Anderson Cancer Center
 
Faculty
Maria E. Cabanillas, MD, FACE
Associate Professor and Faculty Director of Clinical Research,
Dept. of Endocrine Neoplasia & Hormonal Disorders 
University of Texas M.D. Anderson Cancer Center
 
Lori J. Wirth, MD
Medical Director, Head and Neck Oncology  
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
 

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Steven I. Sherman, MD: Consultant, Eisai, Sanofi, Veracyte, Inc., LOXO, Bristol-Myers Squibb, 
Scientific Board Member: Novo Nordisk

Maria E. Cabanillas, MD: Advisory Group Member, LOXO, Blueprint; Principal Investigator, Eisai, Genentech, Inc., Kura, Exelixis

Lori J. Wirth, MD:  Advisory Group Member, Amgen, Eisai, Merck & Co., Blueprint Medicines, Loxo

The following SPC member who reviewed content for this activity reported the following financial relationships:

Giuseppe Barbesino, MD: Spouse, employee of Genzyme

The following SPC Committee members reported financial relationships:

Zahid Ahmad, MD: Research Support, Regeneron, FH Foundation; Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi

Andrew Ahmann, MD: Research Support, DexCom, Lexicon, Medtronic, Novo Nordisk; Consultant, Dexco, Novo Nordisk, Trividia Health

John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals

Natalie Cusano, MD: Research Support, Shire; Speaker, Shire

Joan Han, MD: Research Support, Rhythm Pharmaceutical

Alan Kelly, MD: Speaker, Eli Lilly

E Michael Lewiecki, MD: Consultant, Amgen, Merck, Eli Lilly, Radius Health, Shire, Abbvie and Alexion; Speaker, Alexion, Shire; Research Grant Support, Amgen, Eli Lilly, Merck

Lisa Nachtigall, MD: Consultant, Ipsen, Novartis, Corcept; Grant Support/Investigator, Chiasma

Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships: Connie Newman, MD, Amy Rothberg, MD

Available Credit

  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation

Accreditation Period

Course opens: 
03/30/2017
Course expires: 
04/01/2018